相关实验视频

Updated: Jul 23, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

作为潜在的抗增殖剂的新型强效异环基Grb2-SH2域对抗剂

Vasundhara Singh1, Tarun Pant2, Yatender Kumar3

  • 1Computational and Structural Biology Laboratory, Department of Biological Sciences and Engineering, Netaji Subhas University of Technology, Dwarka, New Delhi, 110078, India.

Biochemical and biophysical research communications
|March 29, 2025
PubMed
概括

研究人员优化了小分子以抑制Grb2-SH2域,这在增殖性疾病中至关重要. 五种新型化合物显示出强大的结合和有利的特性,为新的癌症和心脏缩治疗药物提供了潜力.

关键词:
接收人 接收人表达和净化的表达和净化Grb2-SH2 抗剂的使用在体外试验测试扩散性疾病的扩散性疾病虚拟选是一个虚拟的选.

更多相关视频

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

相关概念视频

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...